Walgreens Boots Alliance ( WBA) finalized a deal with Sycamore Partners worth up to $23.7 billion to take itself private after four months of negotiations, the companies announced Thursday.

Delving into the details, we found 62% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $451,894, and 3 were calls, valued at $464,288.

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are mixed.

CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

CVS sees 23% revenue growth in healthcare benefits & projects 10% EPS in 2025, with Aetna recovery boosting performance. Click here to read why CVS is a Hold.

FTC court order requires CVS Health to share more documents about Caremark Rx PBM practices as part of ongoing investigation into anticompetitive behavior in pharmacy benefits market.

The state’s insurance regulator has demanded detailed information about patients and their medications, raising privacy concerns.